Commercial Coverage: More than 80% of commercial lives covered for Rezdiffra. Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) reported strong net sales of $62 million for the third quarter, driven by ...

Looking back, the first international newsmaker for choral competitions is, of course, the Philippine Madrigal Singers, also known as The Madz, founded in 1963 by Prof. Andrea O. Veneracion ...

More than 20,000 candidates have taken Ballotpedia's candidate survey since we launched it in 2015. Learn more about the survey here. You can ask Oscar Madrigal to fill out this survey by using the ...

Madrigal's Rezdiffra, the first FDA-approved drug for MASH, shows promise but faces competition from GLP-1 drugs and financial challenges in launching in Europe. Despite meeting Phase 3 endpoints ...

Amid rumors of a reboot or cancellation, VPR OG Peter Madrigal is chiming in on where he thinks the show should head. In an interview with the U.S. Sun, Peter was asked his opinion on filming a ...

Partnered with Alan Bersten, she channeled the powerful Luisa Madrigal from Disney's Encanto for a jazz performance. The duo's Encanto-themed performance was part of a Disney-themed episode of DWTS.

Maher channeled the character of Luisa Madrigal, known in the movie for her superhuman strength, with her powerful lifts. She effortlessly lifted Bersten, who was dressed in a full donkey ...

The National Chamber Choir "Madrigal – Marin Constantin," conducted by Anna Ungureanu, continues the tradition of its Christmas concerts, inviting the public in Bucharest to two extraordinary ...

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), with a price target of $390.00. Ed Arce has given his Buy ...

The study has enrolled 845 patients with compensated NASH cirrhosis. Credit: PanuShot / Shutterstock. US-based biopharmaceutical company Madrigal Pharmaceuticals has finished enrolling patients in a ...

Madrigal Pharmaceuticals (MDGL) announced the MAESTRO-NASH OUTCOMES trial evaluating resmetirom for the treatment of patients with compensated NASH cirrhosis has completed enrollment. Bill Sibold ...